GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (OTCPK:KKPCF) » Definitions » E10

KKPCF (Kaken Pharmaceutical Co) E10 : $3.08 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kaken Pharmaceutical Co E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Sep. 2024 was $2.315. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $3.08 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Kaken Pharmaceutical Co's average E10 Growth Rate was 7.50% per year. During the past 3 years, the average E10 Growth Rate was 1.80% per year. During the past 5 years, the average E10 Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Kaken Pharmaceutical Co was 8.50% per year. The lowest was 1.80% per year. And the median was 4.35% per year.

As of today (2024-12-13), Kaken Pharmaceutical Co's current stock price is $24.01. Kaken Pharmaceutical Co's E10 for the quarter that ended in Sep. 2024 was $3.08. Kaken Pharmaceutical Co's Shiller PE Ratio of today is 7.80.

During the past 13 years, the highest Shiller PE Ratio of Kaken Pharmaceutical Co was 21.95. The lowest was 8.02. And the median was 11.68.


Kaken Pharmaceutical Co E10 Historical Data

The historical data trend for Kaken Pharmaceutical Co's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co E10 Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.20 3.97 3.11 2.76

Kaken Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.33 3.48 2.76 2.35 3.08

Competitive Comparison of Kaken Pharmaceutical Co's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Shiller PE Ratio falls into.



Kaken Pharmaceutical Co E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=2.315/108.9000*108.9000
=2.315

Current CPI (Sep. 2024) = 108.9000.

Kaken Pharmaceutical Co Quarterly Data

per share eps CPI Adj_EPS
201412 0.802 97.900 0.892
201503 0.505 97.900 0.562
201506 1.229 98.400 1.360
201509 1.242 98.500 1.373
201512 1.518 98.100 1.685
201603 0.216 97.900 0.240
201606 1.329 98.100 1.475
201609 1.341 98.000 1.490
201612 1.361 98.400 1.506
201703 0.874 98.100 0.970
201706 1.206 98.500 1.333
201709 1.207 98.800 1.330
201712 1.315 99.400 1.441
201803 0.511 99.200 0.561
201806 0.910 99.200 0.999
201809 1.077 99.900 1.174
201812 1.212 99.700 1.324
201903 0.799 99.700 0.873
201906 1.126 99.800 1.229
201909 1.124 100.100 1.223
201912 1.413 100.500 1.531
202003 0.911 100.300 0.989
202006 0.913 99.900 0.995
202009 0.833 99.900 0.908
202012 0.930 99.300 1.020
202103 0.593 99.900 0.646
202106 0.797 99.500 0.872
202109 0.803 100.100 0.874
202112 0.818 100.100 0.890
202203 -0.155 101.100 -0.167
202206 0.574 101.800 0.614
202209 0.568 103.100 0.600
202212 0.630 104.100 0.659
202303 -0.740 104.400 -0.772
202306 0.474 105.200 0.491
202309 0.279 106.200 0.286
202312 0.478 106.800 0.487
202403 0.237 107.200 0.241
202406 0.293 108.200 0.295
202409 2.315 108.900 2.315

Add all the adjusted EPS together and divide 10 will get our e10.


Kaken Pharmaceutical Co  (OTCPK:KKPCF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kaken Pharmaceutical Co's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=24.01/3.08
=7.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Kaken Pharmaceutical Co was 21.95. The lowest was 8.02. And the median was 11.68.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kaken Pharmaceutical Co E10 Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co Headlines

No Headlines